This message was sent to ##Email##
|
|
|
|
|
| |
| ACS CANCER PROGRAMS UPDATES |
ACS
April 7–9, 2019 – Rosemont (Chicago), Illinois
The 2019 Cancer Programs Cluster Workshops will be three individual one-day workshops on consecutive days, in one location, for your convenience. You may attend just one workshop or all three. Sign up here for further information as it becomes available.
ACS
Lymphovascular Invasion, NAACCR Data Item #1182, indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.
Review the primary site, histology and Schema ID for this record, and then follow the coding instructions in STORE. Assign codes for Lymphovascular Invasion, NAACCR Data Item # 1182, based on the absence or presence of lymphovascular invasion as described in the medical record from the checklist or synoptic report, pathology report or a physician’s statement, in that order.
READ MORE
NCCRT
The 2017 national average for CRC screening in HRSA-funded health centers was released last month and is at 42 percent, which increased from 39.9 percent in 2015, meaning an additional 223,100 patients were screened in the last year alone and an additional 467,500 patients were screened in the last 2 years. That’s almost half a million people! Visit the HRSA website for an additional understanding of the rates. View our 80 percent by 2018 Hall of Fame to see the list of these centers that are meeting or exceeding our shared goal. (And if you or a partner you know of is exceeding 80 percent, you can submit them to the Hall of Fame!) Thanks to Laura Makaroff for sharing the data. Most importantly, congratulations to all our colleagues working in health centers, as well as to the many of you who work to support health centers on this continued improvement!
READ MORE
|
Promoted by
|
|
|
|
 |
AJCC
The AJCC Cancer Staging Manual, Eighth Edition is the first edition to have an electronic book (eBook) version. It is available for purchase now on Amazon and is the most current version of the manual (September 2018).
Since 1977, the American Joint Committee on Cancer (AJCC) has published eight editions of cancer staging manuals using contemporary, evidenced-based literature to build a common language of cancer for the care of cancer patients by clinicians and for the cancer surveillance community. The print version of the eighth edition was first published in October 2016 and went into effect for all cancer cases diagnosed on or after Jan. 1, 2018. The eighth edition presents evidence-based revisions for the staging of cancer for a number of organ sites. The chapters include the rationale and rules for staging; the definitions of tumor, lymph node involvement and metastasis; stage groupings; and histologic grade.
There have been updates since the first printing of the eighth edition, all of which are incorporated in this eBook version available through Amazon’s Kindle. The Kindle version can be used on any device (PC, MAC, iPhone, iPad, Android) with the free Kindle app. The electronic version allows for highlighting, adding notes and bookmarks and creating flashcards. The AJCC has a curated FAQ document to address common questions that can be accessed at cancerstaging.org. All other questions related to the eighth edition can be sent to ajcc@facs.org.
READ MORE
 |
|
Our ihcDirect® method yields a revolutionary technology that opens a spectrum of new clinical applications including intraoperative surgery. Using the Novodiax PolyHRP technology, Intraoperative IHC tests can now be completed in just 10 minutes using fresh frozen tissues.
For more details, see our
 ihcDirect® product list.
|
|
Clinical Research Program
As mentioned in prior communications, the 2018 DCIS Special Study opened July 16. We invite you to visit the 2018 Special Study on DCIS SharePoint site, which will house all materials you will need to participate in the study. We have created a universal login for this site; please note it is case sensitive:
Login: DCISStudy
Password: study2018.
All registrars and co-registrars will be able to access and download materials via the SharePoint site.
READ MORE
| HEALTH CARE NEWS AND UPDATES |
ScienceDaily
Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects especially when treating tumors. Scientists have now described novel conjugates made from antibodies and a kinesin spindle protein inhibitor. Changing the linker between the two components allows for tuning the activity of this cytostatic drug, which is effective against a broad palette of cancers.
READ MORE
|
Promoted by
|
|
|
|
 |
Medical Xpress
A natural plant compound exploits a newly identified Achilles' heel in a cancer of the eye, uveal melanoma. In human cancer cells growing in the lab, the compound shuts down the overactive signaling that drives uveal melanoma cell growth, according to researchers at Washington University School of Medicine in St. Louis.
READ MORE
Health Imaging
Researchers from the Norwegian University of Science and Technology in Trondheim, Norway have found that having a large brain — or greater intracranial volume — increases the risk for brain cancer.
"Several studies have shown that the size of different organs is an important factor in cancer development. For example, women with larger breasts have a greater risk of breast cancer. We wanted to check if this was also the case for brain tumors," lead author Even Hovig Fyllingen, a PhD candidate at NTNU, said in a prepared statement.
READ MORE
 |
|
Dynamic online courses from the Association of Community Cancer Centers (ACCC) offer the tools your staff needs to help patients pay for treatment—while maximizing reimbursement at your cancer program. The Financial Advocacy Boot Camp explains all aspects of financial advocacy and is a great resource for new advocates and experienced professionals. Your team will be more prepared with this online curriculum. Learn More
|
|
Cancer Network
Response to immunotherapy with checkpoint inhibitors among patients with metastatic renal cell carcinoma did not diminish when given as first-line therapy compared with fourth-line therapy, according to a retrospective study published in Cancer.
Additionally, researchers led by Steven M. Yip, MD, MSc, of Tom Baker Cancer Center, Calgary, Canada, showed that the International Metastatic Renal Cell Carcinoma Database Consortium risk category criteria appropriately stratified patients into risk categories.
READ MORE
Medical News Today
Two recent studies detail a natural mechanism that, if harnessed properly, may be able to destroy cancer cells and their ability to become resistant to treatment — without any of the side effects of chemotherapy. In a study published last year, scientists led by Marcus E. Peter — the Tomas D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine in Chicago, IL — revealed not only that certain RNA molecules can kill cancer cells, but that they can also simultaneously prevent them from becoming resistant to treatment.
READ MORE
 |
|
Clinical Cancer Coding is hard. HLA-Global’s Horizon uses advanced AI and Machine Learning to make the hard easy. Horizon has an average accuracy of 97%+ all of the time, works 24X7, costs 50% less than manual coders and continually learns. And it handles the new 2018 standards. For further information visit www.hla-global.com.
|
|
ScienceDaily
Biophysicists have demonstrated that Raman microscopy can be used to detect the resistance of tumor cells to cancer drugs. Unlike conventional approaches, this method does not require any antibodies or markers. It detects the response of cells to administered drugs and therefore could determine the effect of drugs in preclinical studies.
READ MORE
Healio
American Cancer Society presented its Medal of Honor to five individuals during a ceremony in Washington.
The Medal of Honor — the society’s highest award — recognizes individuals who have made valuable contributions in the fight against cancer through basic research, clinical research or cancer control.
READ MORE
Health Imaging
A new imaging collaboration between researchers at the Walter and Eliza Hall Institute’s Center for Dynamic Imaging in Australia has revealed cancer cell findings that may help predict how cells respond to chemotherapy and our overall understanding of the disease, according to a release from the Institute.
"This study demonstrates the power of imaging to directly reveal cellular behaviors, and in some cases challenge assumptions that were made before it was possible to obtain such clear evidence," researcher Lachlan Whitehead, MD, said in the release.
READ MORE
| IMPORTANT DATES AND DEADLINES |
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
